# Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

> **NCT05690204** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanton Pharma Pte. Ltd.** · enrollment: 87 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** SAP-001

## Key facts

- **NCT ID:** NCT05690204
- **Lead sponsor:** Shanton Pharma Pte. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-12
- **Primary completion:** 2025-01
- **Final completion:** 2025-02
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05690204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05690204, "Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05690204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*